We are proud to announce that our innovation Cymoplive has been hand-picked after a rigorous selection process for 2024’s EIC pioneer program by the prestigious EIC T2M initiative of EU. (link: https://eic.ec.europa.eu/eic-funding-opportunities/business-acceleration-services/tech-market-programme-t2m_en). Under this program, a curated team of technology and business developers led by Dr. Biswajoy Ghosh will be trained on innovation, and provided a platform to prepare Cymoplive for commercialization. Cymoplive is a ground breaking 3D cell motility assay, that promises to unlock the secrets of cells’ mechanical behaviour in response to disease and therapy. It will make therapy more personalized, targeted and pre-tested for a variety of diseases and health conditions. Cymoplive is being personally mentored by Dr. Guillaume Berteloot (https://www.linkedin.com/in/guillaumeberteloot/?locale=en_US) of Deep Tech Founders (https://deeptechfounders.com/about-us), and accelerating its journey to commercialization.
